Literature DB >> 34912062

Stomach cancer gets a triple punch of therapy.

Myriam Chalabi.   

Abstract

Entities:  

Keywords:  Cancer; Immunology; Medical research

Mesh：

Year:  2021        PMID： 34912062     DOI： 10.1038/d41586-021-03458-7

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

4.  Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Authors:  Victor A Gall; Anne V Philips; Na Qiao; Karen Clise-Dwyer; Alexander A Perakis; Mao Zhang; Guy T Clifton; Pariya Sukhumalchandra; Qing Ma; Sangeetha M Reddy; Dihua Yu; Jeffrey J Molldrem; George E Peoples; Gheath Alatrash; Elizabeth A Mittendorf
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

5.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Authors:  Kohei Shitara; Yung-Jue Bang; Satoru Iwasa; Naotoshi Sugimoto; Min-Hee Ryu; Daisuke Sakai; Hyun-Cheol Chung; Hisato Kawakami; Hiroshi Yabusaki; Jeeyun Lee; Kaku Saito; Yoshinori Kawaguchi; Takahiro Kamio; Akihito Kojima; Masahiro Sugihara; Kensei Yamaguchi
Journal:  N Engl J Med       Date:  2020-05-29       Impact factor: 91.245

6.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Authors:  Yelena Y Janjigian; Kohei Shitara; Markus Moehler; Marcelo Garrido; Pamela Salman; Lin Shen; Lucjan Wyrwicz; Kensei Yamaguchi; Tomasz Skoczylas; Arinilda Campos Bragagnoli; Tianshu Liu; Michael Schenker; Patricio Yanez; Mustapha Tehfe; Ruben Kowalyszyn; Michalis V Karamouzis; Ricardo Bruges; Thomas Zander; Roberto Pazo-Cid; Erika Hitre; Kynan Feeney; James M Cleary; Valerie Poulart; Dana Cullen; Ming Lei; Hong Xiao; Kaoru Kondo; Mingshun Li; Jaffer A Ajani
Journal:  Lancet       Date:  2021-06-05       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.